vs
Side-by-side financial comparison of FIRSTSUN CAPITAL BANCORP (FSUN) and Vanda Pharmaceuticals Inc. (VNDA). Click either name above to swap in a different company.
FIRSTSUN CAPITAL BANCORP is the larger business by last-quarter revenue ($110.0M vs $57.2M, roughly 1.9× Vanda Pharmaceuticals Inc.). FIRSTSUN CAPITAL BANCORP runs the higher net margin — 19.6% vs -246.8%, a 266.4% gap on every dollar of revenue. Over the past eight quarters, Vanda Pharmaceuticals Inc.'s revenue compounded faster (9.8% CAGR vs 6.9%).
FirstSun Capital Bancorp is a U.S.-headquartered financial holding company that offers a comprehensive range of banking and financial services, including commercial and consumer lending, deposit products, wealth management, and treasury solutions. It mainly serves individual customers, small and medium-sized enterprises, and corporate clients across U.S. regional markets.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
FSUN vs VNDA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $110.0M | $57.2M |
| Net Profit | $21.6M | $-141.2M |
| Gross Margin | — | — |
| Operating Margin | — | -70.5% |
| Net Margin | 19.6% | -246.8% |
| Revenue YoY | — | 7.6% |
| Net Profit YoY | -8.4% | -2774.3% |
| EPS (diluted) | $0.76 | $-2.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $110.0M | — | ||
| Q4 25 | $110.2M | $57.2M | ||
| Q3 25 | $107.3M | $56.3M | ||
| Q2 25 | $105.6M | $52.6M | ||
| Q1 25 | $96.2M | $50.0M | ||
| Q4 24 | $98.7M | $53.2M | ||
| Q3 24 | $98.2M | $47.7M | ||
| Q2 24 | $96.2M | $50.5M |
| Q1 26 | $21.6M | — | ||
| Q4 25 | $24.8M | $-141.2M | ||
| Q3 25 | $23.2M | $-22.6M | ||
| Q2 25 | $26.4M | $-27.2M | ||
| Q1 25 | $23.6M | $-29.5M | ||
| Q4 24 | $16.4M | $-4.9M | ||
| Q3 24 | $22.4M | $-5.3M | ||
| Q2 24 | $24.6M | $-4.5M |
| Q1 26 | — | — | ||
| Q4 25 | 29.0% | -70.5% | ||
| Q3 25 | 26.4% | -55.6% | ||
| Q2 25 | 31.2% | -73.2% | ||
| Q1 25 | 30.9% | -82.0% | ||
| Q4 24 | 20.4% | -19.3% | ||
| Q3 24 | 29.1% | -23.1% | ||
| Q2 24 | 32.3% | -20.1% |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 22.5% | -246.8% | ||
| Q3 25 | 21.6% | -40.1% | ||
| Q2 25 | 25.0% | -51.7% | ||
| Q1 25 | 24.5% | -58.9% | ||
| Q4 24 | 16.6% | -9.2% | ||
| Q3 24 | 22.8% | -11.2% | ||
| Q2 24 | 25.5% | -9.0% |
| Q1 26 | $0.76 | — | ||
| Q4 25 | $0.89 | $-2.40 | ||
| Q3 25 | $0.82 | $-0.38 | ||
| Q2 25 | $0.93 | $-0.46 | ||
| Q1 25 | $0.83 | $-0.50 | ||
| Q4 24 | $0.57 | $-0.09 | ||
| Q3 24 | $0.79 | $-0.09 | ||
| Q2 24 | $0.88 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $413.7M | $84.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $327.2M |
| Total Assets | $8.6B | $488.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $413.7M | — | ||
| Q4 25 | $652.6M | $84.9M | ||
| Q3 25 | $659.9M | $70.0M | ||
| Q2 25 | $785.1M | $81.0M | ||
| Q1 25 | $621.4M | $111.8M | ||
| Q4 24 | $615.9M | $102.3M | ||
| Q3 24 | $573.7M | $100.5M | ||
| Q2 24 | $535.8M | $103.0M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $327.2M | ||
| Q3 25 | $1.1B | $466.0M | ||
| Q2 25 | $1.1B | $486.3M | ||
| Q1 25 | $1.1B | $511.4M | ||
| Q4 24 | $1.0B | $538.5M | ||
| Q3 24 | $1.0B | $541.2M | ||
| Q2 24 | $996.6M | $542.5M |
| Q1 26 | $8.6B | — | ||
| Q4 25 | $8.5B | $488.9M | ||
| Q3 25 | $8.5B | $601.1M | ||
| Q2 25 | $8.4B | $624.7M | ||
| Q1 25 | $8.2B | $631.9M | ||
| Q4 24 | $8.1B | $656.2M | ||
| Q3 24 | $8.1B | $645.1M | ||
| Q2 24 | $8.0B | $651.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-29.4M |
| Free Cash FlowOCF − Capex | — | $-29.5M |
| FCF MarginFCF / Revenue | — | -51.6% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-110.4M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $111.5M | $-29.4M | ||
| Q3 25 | $49.4M | $-31.6M | ||
| Q2 25 | $15.0M | $-15.3M | ||
| Q1 25 | $26.4M | $-33.1M | ||
| Q4 24 | $101.1M | $-1.8M | ||
| Q3 24 | $48.1M | $-14.6M | ||
| Q2 24 | $20.9M | $-6.9M |
| Q1 26 | — | — | ||
| Q4 25 | $104.0M | $-29.5M | ||
| Q3 25 | $47.6M | $-31.8M | ||
| Q2 25 | $13.0M | $-15.6M | ||
| Q1 25 | $24.3M | $-33.6M | ||
| Q4 24 | $95.7M | $-2.0M | ||
| Q3 24 | $47.1M | $-14.7M | ||
| Q2 24 | $19.9M | $-7.0M |
| Q1 26 | — | — | ||
| Q4 25 | 94.3% | -51.6% | ||
| Q3 25 | 44.4% | -56.5% | ||
| Q2 25 | 12.3% | -29.6% | ||
| Q1 25 | 25.3% | -67.1% | ||
| Q4 24 | 97.0% | -3.8% | ||
| Q3 24 | 47.9% | -30.9% | ||
| Q2 24 | 20.6% | -13.9% |
| Q1 26 | — | — | ||
| Q4 25 | 6.8% | 0.2% | ||
| Q3 25 | 1.6% | 0.3% | ||
| Q2 25 | 1.9% | 0.6% | ||
| Q1 25 | 2.1% | 0.9% | ||
| Q4 24 | 5.5% | 0.4% | ||
| Q3 24 | 1.1% | 0.3% | ||
| Q2 24 | 1.1% | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | 4.49× | — | ||
| Q3 25 | 2.13× | — | ||
| Q2 25 | 0.57× | — | ||
| Q1 25 | 1.12× | — | ||
| Q4 24 | 6.18× | — | ||
| Q3 24 | 2.15× | — | ||
| Q2 24 | 0.85× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FSUN
| Net Interest Income | $82.8M | 75% |
| Noninterest Income | $27.2M | 25% |
VNDA
| Fanapt | $33.2M | 58% |
| Hetlioz | $16.4M | 29% |
| PONVORY | $7.6M | 13% |
